Mondego Bio

Mondego Bio is a private, preclinical-stage biotech developing novel oral PTPN2 inhibitors to overcome resistance in cancer immunotherapy. The company's lead candidate, ZE00-0388, has demonstrated strong target inhibition, high selectivity, and promising efficacy in preclinical models, leading to the selection of a clinical candidate in late 2025. Backed by a syndicate of top-tier life science investors including Biovance Capital, OrbiMed, and Torrey Pines, Mondego is targeting the initiation of first-in-human clinical trials in the first half of 2026.

Development of highly selective, orally bioavailable small molecule inhibitors targeting the PTPN2 phosphatase to enhance interferon-gamma signaling and overcome resistance in cancer immunotherapy.

PTPN2 is a recognized target in immuno-oncology, attracting interest from both biotech and large pharmaceutical companies. Competition includes other small-molecule developers and potentially alternative modalities (e.g., degraders). Mondego's claimed differentiation lies in the high selectivity and oral bioavailability of its candidates, aiming for a best-in-class profile.